Drug lab interactions-
Possibilty of a false positive HIV test with ELISA assay, a confirmatory western blot test would be
expected to be negative.
Enfluviride has not been studied in non-HIV  infected individuals

HIV infection

Adverse reactions-

Infections -  herpes simplex  4%  influenza 3%    sinusitis 6%   skin papilloma   4%

GI -    constipation    3%   upper  abdominal pain   2%  pancreatitis  2%

Hematologic -    lymphadenopathy   2%

Musculoskeletal -  myalgia  4%

Ophthalmic -   conjuntivitis   2%

Respiratory -  cough  7%

Miscellaneous -   anorexia   2%   decreased appetite 6%   decreased weight 6%
                              influenzal like illness    2%

Hypersensitivity to enfuviride or its components

Special precautions-

Local site reactions- most common adverse reactions associated with enfuvirtide use

Pneumonia-  Occured in treated subjects, Risk factors for pneumonia include low initial
CD4 count, high initial viral load,IV drug use, smoking, and history of lung disease

Hazardous reactions- patientsexperiencing dizziness while taking enfuvirtide, should be
adviced to talk to their doctor   before driving or operating machinery

Pregnancy - the drug should be used during pregnancy only if clearly needed.

Lactation- mothers should be instructed not to breast feed if they receiving enfuvirtide

Children- safety for use in pediatric patients below 6 years of age have not been established

Elderly- Adequate clinical stidies not done in elderly patients above 65 years of age.
Excercise caution while administering to patients above 65 years of age.

Indication-
HIV infection

Dosage-                                                                                                                                                   Adults - 90mg ( 1ml ) twice daily injected SC into the upper arm , anterior thigh
or abdomen. Each injection should be given at a site different from the preceeding
 injection site, and only where there is no current injection site reactionfrom the earlier
dose.
Enfuvirtide should not be injected into moles, scar tissuue, bruises, or the navel.

Children- no data available to establish dose recommendation of pediatric patients
below the age of 6 years

In pediatric patients 6 years through 16 years of age the recommended dose of 90mg
twice daily injected into upper arn, anterior thigh or abdomen.
Each injection should be given at a site different from the preceeding  injection site,
and only where there is no current injection site reactionfrom the earlier dose.

1. Patients should be informed that injection site reaction occur commonly and made aware of
   the injection instructions

2, Patients should report promptly about the reactions, anf for signs or symptoms of cellilitis
    or local infection.

3. Patients should be aware about the increased rate of bacterial  pneumonia that may occur

4. Patients should be made aware of the hypersensitivity reactions and they should report
   promptly, if rash ,fever, nausea, vomiting, chills, rigors, hypotension, and elevated serum
   liver transaminse occur

5. Patients should be aware that enfuvirtide is not a cure for HIV infections and patients may
   continue to  contact illness associated with HIV infection.

6. Patients should inform their doctor if they are pregnant or plan to become pregnant
    while taking this medication

7. Patients , if they  experience dizzines while taking taking this medication, should nor drive
    or operate any hazardous machinery.

Pregnancy -
The drug should be used during pregnancy only if clearly needed.

Lactation-                                                                                                                                                  Mothers should be instructed not to breast feed if they receiving enfuvirtide

Children-
Safety for use in pediatric patients below 6 years of age have not been established

Elderly-
Adequate clinical stidies not done in elderly patients above 65 years of age.
Excercise caution while administering to patients above 65 years of age.